• Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact

Barry A. Friedman, PhD LLC

FDA Regulatory Compliance for the Pharmaceutical, Biotechnology and Medical Device Arenas

VUAB PHARMA, CZECH REPUBLIC, RECEIVES WARNING LETTER (MAY 27, 2015, con’t)

June 24, 2015 By Barry Friedman Leave a Comment

Objectionable Bacillus spp. Found During Customer Sampling  During the FDA’s inspection of VUAB Pharma a.s., Vltayska 53, Roztoky, Czech Republic, from June 09, 2014, through June 13, 2014, an investigator from the U.S. Food and Drug Administration (FDA) identified significant deviations from current good manufacturing practice (CGMP) for the … [Read more...]

VUAB PHARMA, CZECH REPUBLIC, RECEIVES WARNING LETTER (MAY 27, 2015)

June 5, 2015 By Barry Friedman Leave a Comment

Objectionable Anaerobe Found During Customer Sampling During the FDA’s inspection of VUAB Pharma a.s., Vltayska 53, Roztoky, Czech Republic, from June 09, 2014, through June 13, 2014, an investigator from the U.S. Food and Drug Administration (FDA) identified significant deviations from current good manufacturing practice (CGMP) for the manufacture of active … [Read more...]

MICRO LABS LIMITED, VERNA, INDIA RECEIVES WARNING LETTER (01/09/15)

March 4, 2015 By Barry Friedman Leave a Comment

The FDA inspected Micro Labs Limited, located at Plot No. S-155 to S-159, Phase III, Verna Industrial Estate, Verna, India, between May 5-10 and 12-13, 2014. Investigators from the U.S. Food and Drug Administration (FDA) identified significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals, Title 21, Code of Federal … [Read more...]

ID BIOMEDICAL CORP RECEIVES WARNING LETTER (6/12/14)

June 25, 2014 By Barry Friedman Leave a Comment

COMPANY CONTINUED TO FIND GRAM NEGATIVES IN PW WATER SYSTEM ID Biomedical Corp, a subsidiary of GSK Biologicals, located in Quebec, Canada was audited by the FDA from March 31 through April 9, 2014.  The FDA Investigators documented deviations from CGMP in the manufacture of their biological drug product, Flulaval and its intermediates.  Significant objectionable conditions … [Read more...]

Wockhardt’s Walui and Chikalthana Facilities, Maharasthtra Receive Warning Letter (11/25/13)

December 3, 2013 By Barry Friedman Leave a Comment

Data Manipulation Continues to be a Major Issue  After a somewhat quiet month, CDER is again active in India.  Their current concern is with a Company that should be familiar to each of us.  And the issues in many cases are similar to those found within a Warning Letter issued in July of this year.  Alexander Gaffney, RAPS Editor, has put together an excellent summary of this … [Read more...]

Next Page »
New Reader? Learn More

Connect With Me:

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Webinar Registration & Information

FREQUENTLY ASKED QUESTIONS:

FDA Form 483 Frequently Asked Questions

USP General Chapter

USP General Chapter 62, Part II

TOP OBSERVATIONS:

FDA’s CDER LISTING OF TOP NINETEEN OBSERVATIONS FOR 2014

FDA CDER Most Frequent Form FDA 483 Observations Fiscal Year 2012

CDER MOST FREQUENTLY CITED DRUG OBSERVATIONS – FISCAL YEAR 2010

Top Posts:

Top Posts for 2012

Top Posts for 2013

Top Posts Year To Date

Recent Posts

  • Upcoming Microbiological Webinars
  • Microbiological Webinars
  • Microbiological Webinars 2020 (Upcoming)
  • General Chapter (USP<60>) on B. cepacia Complex to Issue December 1, 2019
  • Les Produits Chimiques B.G.R., Inc. Receives FDA Warning Letter (07/24/2018) for Failure to Perform Laboratory Testing

Categories

follow us in feedly
  • Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact
  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Thank You For Visiting Barry A. Friedman, PhD LLC - 2015

Welcome To My Blog!
Please enter your name and email below to receive my newsletter.
Your information will *never* be shared or sold to a 3rd party.